Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Appendix B

CDC and Council of State and Territorial Epidemiologists (CSTE) pertussis case definition*

Clinical Case Definition

  • a cough illness lasting at least 2 weeks with one of the following: paroxysms of coughing, inspiratory "whoop," or posttussive vomiting, and without other apparent cause (as reported by a health-care professional)

Laboratory Criteria for Diagnosis

  • isolation of Bordetella pertussis from a clinical specimen, or
  • positive polymerase chain reaction (PCR) assay for B. pertussis

Case Classification

Confirmed

  • an acute cough illness of any duration associated with B. pertussis isolation, or
  • a case that meets the clinical case definition and is confirmed by PCR, or
  • a case that meets the clinical definition and is epidemiologically linked directly to a case confirmed by either culture or PCR

Probable

  • a case that meets the clinical case definition, is not laboratory confirmed by culture or PCR, and is not epidemiologically linked directly to a laboratory-confirmed case.

SOURCES: Guidelines for the control of pertussis outbreaks. Atlanta, GA: CDC. Available at http://www.cdc.gov/nip/publications/pertussis/guide.htm. Council of State and Territorial Epidemiologists. CSTE position statement, 1997-ID-9: Public health surveillance control and prevention of pertussis, available at http://www.cste.org/ps/1997/1997-id-09.htm.

* Both probable and confirmed cases should be reported to the National Notifiable Diseases Surveillance System (http://www.cdc.gov/epo/dphsi/nndsshis.htm).

Appendix C: Summary of recommendations for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) and tetanus and diphtheria toxoids (Td) use among adolescents aged 11--18 years

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.


References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 3/9/2006

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services